Compare Stocks → get a piece of the profit from this land (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:ONCOTCMKTS:OPTI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeONCOncolytics BiotechC$1.51-2.6%C$1.49C$1.20▼C$4.49C$113.88M1.4972,774 shs63,477 shsOPTIOptec International$0.00$0.00$0.00▼$0.00$19KN/A38.56 million shs9.28 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceONCOncolytics Biotech0.00%-5.03%+5.59%-3.21%-29.11%OPTIOptec International0.00%-37.01%-40.74%-57.33%+433.33%get a piece of the profit from this land (Ad)This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationONCOncolytics Biotech0.9186 of 5 stars3.50.00.00.02.30.00.0OPTIOptec InternationalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceONCOncolytics Biotech3.00BuyC$6.00297.35% UpsideOPTIOptec InternationalN/AN/AN/AN/ACurrent Analyst RatingsLatest DEST, ONC, OPTI, and OBD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ONCOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperformC$3.00(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookONCOncolytics BiotechN/AN/AC$0.36 per share4.22C$0.31 per shareN/AOPTIOptec InternationalN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateONCOncolytics Biotech-C$28.21M-C$0.41N/A∞N/AN/A-115.80%-63.83%8/12/2024 (Estimated)OPTIOptec InternationalN/AN/A0.00∞N/AN/AN/AN/AN/ALatest DEST, ONC, OPTI, and OBD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCOncolytics Biotech-C$0.15-C$0.05+C$0.10-C$0.05N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthONCOncolytics BiotechN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioONCOncolytics Biotech4.918.148.86OPTIOptec InternationalN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipONCOncolytics Biotech6.71%OPTIOptec InternationalN/AInsider OwnershipCompanyInsider OwnershipONCOncolytics Biotech3.90%OPTIOptec International50.34%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableONCOncolytics Biotech2975.42 millionN/ANot OptionableOPTIOptec International111.65 millionN/ANot OptionableDEST, ONC, OPTI, and OBD HeadlinesRecent News About These CompaniesMay 18 at 12:17 AM | eurekalert.orgIso-propagation vortices: optical multiplexing for unprecedented information capacityMay 13, 2024 | tmcnet.comIDTechEx Release New Global Optical & Radio Frequency Metamaterials Market ReportMay 6, 2024 | fmiblog.comGlobal Optical Coherence Tomography IndustryMay 3, 2024 | sgbonline.comZeroTech Optics Appoints Lead for International SalesApril 16, 2024 | invisionmag.comNearly 100 Optical Industry Executives Convene for The Vision Council’s Lab Leadership ForumApril 12, 2024 | optics.orgSPIE Optical Systems Design: reviewing Kingslake and polishing up ELTMarch 25, 2024 | msn.comAdvancements in Optical Fiber Manufacturing Aboard the ISSMarch 6, 2024 | br.advfn.comOPTEC INTERNATIONAL'S RECENT ACQUISITION OF ARTIFICIAL INTELLIGENCE DRIVEN MEDTECH COMPANY WITH SALES OF $59 MILLION...February 27, 2024 | globenewswire.comRB Capital Partners, Inc. Officially Moves Forward with Appointment of a Receiver for Optec International, Inc.February 20, 2024 | hackaday.comoptical mouseFebruary 20, 2024 | opprairie.comDive Deeper Into Trends, Challenges, And Opportunities Of The Global Optical Cable Crossing Connection Cabinet MarketFebruary 16, 2024 | hackaday.comoptical illusionFebruary 15, 2024 | opprairie.comChanging Dynamics Of The Global Handheld Optical Coherence Tomography (OCT) Device Market In The Coming YearsFebruary 15, 2024 | devdiscourse.comSTL fosters cultural and community connections with its Optical solutions in BAPS temple, Abu DhabiFebruary 14, 2024 | opprairie.comChanging Dynamics Of The Global Optical Loop Market In The Coming YearsFebruary 12, 2024 | markets.businessinsider.comRB Capital Partners, Inc. Announces Shareholder Update for Optec International, Inc.February 5, 2024 | opprairie.comOptical Limiter Market Dynamics: A Strategic Market OverviewFebruary 5, 2024 | opprairie.comExploring The Applications Of Optical Phase Demodulator Market In The Coming YearsFebruary 4, 2024 | richlandsource.comOptimist Club celebrates International Optimist Day with preschool field tripFebruary 2, 2024 | opprairie.comChanging Dynamics Of The Global Optical pH Sensors Market In The Coming YearsNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks 3 High-performing Stocks That Could Rip Once Markets Turn Back UpApril 26, 2024 8:59 AMView 3 High-performing Stocks That Could Rip Once Markets Turn Back UpMarketBeat Week in Review – 4/15 - 4/19April 20, 2024 7:00 AMView MarketBeat Week in Review – 4/15 - 4/19Western Digital Slips Despite EPS Beat and Raise - Buy Time? April 29, 2024 7:45 AMView Western Digital Slips Despite EPS Beat and Raise - Buy Time? Unity Software’s Mixed Q1, But Long-Term Outlook Remains PositiveMay 10, 2024 10:17 AMView Unity Software’s Mixed Q1, But Long-Term Outlook Remains PositiveAll HeadlinesCompany DescriptionsOncolytics BiotechTSE:ONCOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Optec InternationalOTCMKTS:OPTIOptec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
